These results suggest that 1-PPA treatment can protect from tissue damage and multi-organ failure induced by LPS in experimental sepsis, providing evidence that PAR2 inhibition is a crucial event in preventing the activation of pathways leading to cytokine release, hypercoagulable state, and vasodilation, which are the hallmarks of septic shock. The gene discussed is F2RL1; the disease is septic shock.